Figure 3: VPS9D1-AS1 sponges miR-187-3p in prostate cancer. (a) Locations of VPS9D1-AS1 in the nucleus and cytoplasm were observed in the subcellular fractionation assay. (b) Volcano plot of differentially expressed miRNAs in prostate cancer in The Cancer Genome Atlas (TCGA) database, in which upregulated and downregulated miRNAs in prostate cancer are expressed as red dots and green dots respectively. (c) Venn diagram of intersecting miRNAs that share binding site with VPS9D1-AS1 in starBase database/differentially downregulated miRNAs in prostate cancer in TCGA database. (d) Heat map of correlative analysis on the expressions of VPS9D1-AS1, miR-187-3p, and miR-23c in TCGA database. (e) MiR-187-3p level in prostate cancer tissues (red) and normal tissues (green). (f) MiR-187-3p expression in RWPE-1, VCaP, PC-3, and DU-145 cells was examined via quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) *P < 0.05 relative to the RWPE-1 group, n = 3. (g) Binding site of VPS9D1-AS1-Wt and miR-187-3p in starBase database. (h) The binding relationship between VPS9D1-AS1 and miR-187-3p was verified in dual-luciferase assy. *P < 0.05 relative to VPS9D1-AS1-Wt + negative controls (NC)-mimic group, n = 3. (i) The interplay between VPS9D1-AS1 and miR-187-3p was confirmed in the RIP assay. *P < 0.05 relative to IgG group, n = 3. (j) The impact of silencing VPS9D1-AS1 on miR-187-3p expression in PC-3 cells was assessed utilizing qRT-PCR. *P < 0.05 relative to sh-NC group, n = 3.